ACT, CO and MO biomodulation protocols based on REAC® Technology at the Lipedema World Congress 2025
Lipedema is one of the most complex challenges in modern medicine: a chronic condition characterised by a symmetrical accumulation of adipose tissue, often associated with chronic pain, oedema, inflammation, circulatory dysfunction and metabolic alterations. In this context, the Lipedema World Congress confirms its role as an international reference event for the scientific and clinical community, bringing together lymphologists, angiologists, plastic surgeons, physiatrists, nutritionists and specialists in regenerative medicine to share the latest advances in diagnosis, pathophysiology and therapy.
Among the companies present, REAC Technology – produced exclusively by ASMED® Srl – contributes to the field of non-invasive biomodulation. At their stand, visitors have the opportunity to learn more about the specific REAC® protocols designed to act on the key mechanisms of lipedema:
• ACT (Anti-inflammatory Anti-cellulite): aimed at reducing systemic and localised inflammation, improving microcirculation, lymphatic drainage and skin elasticity.
• CO (Circulation Optimization): optimises blood flow, reduces edema and promotes lymphatic drainage, relieving the feeling of heaviness in the limbs.
• MO (Metabolic Optimization): supports the restoration of cellular metabolic balance, improving energy efficiency and contributing to the management of the insulin resistance often associated with the condition.
REAC® protocols are based on the use of low-intensity asymmetric radioelectric fields that modulate endogenous bioelectrical activity, promoting cellular and tissue repair processes. The inventors of the technology, Prof. Salvatore Rinaldi and Dr Vania Fontani of the Rinaldi Fontani Institute, are present to illustrate the mechanisms of action and share the clinical experience gained.
The approach is supported by peer-reviewed publications indexed in PubMed (authors Rinaldi and Fontani), which document the effectiveness of REAC® in reducing chronic pain, oedema and improving circulatory and metabolic parameters in lipedema-related conditions, including rheumatoid arthritis, fibromyalgia and postmenopausal lipodystrophy.
In a therapeutic landscape where effective and safe conservative options are still limited, REAC® Technology is proposed as a complementary tool, easily integrated into multidisciplinary pathways, non-invasive and well tolerated.
Physicians interested in the scientific rationale and clinical applications can consult the studies published on PubMed and the website of the Rinaldi Fontani Institute.
